Harmony Biosciences Holdings, Inc. ("Harmony" or the "Company") (Nasdaq: HRMY), a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases, today commented on the favorable decision by the U.S. Patent and Trademark Office (USPTO) to deny a Petition for Reexamination concerning a patent covering the active ingredient in WAKIX® (pitolisant).
https://finance.yahoo.com/news/harmony-biosciences-reiterates-confidence-wakix-120000239.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.